Overview

This trial is active, not recruiting.

Condition breast cancer
Treatment the survivor stories tablet
Sponsor Washington University School of Medicine
Start date November 2009
End date January 2015
Trial size 220 participants
Trial identifier NCT00929084, 000799

Summary

The purpose of this study is to evaluate in a randomized controlled trail, an innovative cancer communication strategy to help African American breast cancer patients cope with a variety of challenges during and after treatment and to better adhere to recommended treatment guidelines and follow-up care.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose health services research
Arm
(Other)
Women in the Survivor Stories intervention arm will be given the Survivor Stories Tablet to take home for two weeks at three different time points over a two year period.
the survivor stories tablet
The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
(Other)
Women in the Control Arm will receive standard care.
the survivor stories tablet
The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.

Primary Outcomes

Measure
Determine to what extent African American breast cancer survivor stories affect various aspects of QOL, including depressed mood and concern about recurrence, among African American breast cancer patients following primary treatment.
time frame: Outcome measures are assessed at five time points: baseline, one month following primary treatment surgery, 6 months, one year, and two years post surgery.

Secondary Outcomes

Measure
Determine whether and to what extent African American breast cancer survivor stories affect African American breast cancer patients' adherence to recommended surveillance mammography and prescribed hormone therapy
time frame: Outcome measures are assessed at five time points: baseline, one month following primary treatment surgery, 6 months, one year, and two years post surgery.

Eligibility Criteria

Female participants at least 30 years old.

Inclusion Criteria: - African American women - First primary ductal carcinoma in situ (DCIS) or stages I, II, or III invasive breast cancer. Exclusion Criteria: - Prior DCIS or breast cancer diagnosis - Stage IV or metastatic breast cancer - Having received double mastectomy - non-English speaking, - Having known psychiatric or neurologic disorders - Being cognitively impaired according to weighted error scores on the Orientation-Memory-Concentration Test - Being unwilling or unable to give consent

Additional Information

Official title Survivor Stories: Impact on Cancer Patients' Quality of Life and Follow-up
Principal investigator Donna B Jeffe, PhD
Description Disparities in incidence and mortality between African Americans and Caucasians for a number of cancers have been well documented. This study builds on previous work in St. Louis to overcome barriers to access to breast screening, identifying and addressing factors associated with access to care once diagnosed, and factors contributing to delay in diagnosis and completion of therapy. African American breast cancer patients randomly assigned to the intervention arm of the trial will have access to the Survivor Stories Tablet, a tablet computer, on which they will browse an archive of 1-3 minute videotaped survivor stories about five topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer. Patients will have the tablet for two weeks after enrollment in the study, and again at 6 and 12 months. Patients in the control arm will receive usual care.
Trial information was received from ClinicalTrials.gov and was last updated in February 2015.
Information provided to ClinicalTrials.gov by Washington University School of Medicine.